Side-by-side financials for ESPR and NVS. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ESPR | NVS |
|---|---|---|
| Market cap | - | $292.08 B |
| US-listed rank | - | #47 |
| Revenue (latest FY) | $403.13M | - |
| Net income (latest FY) | -$22.68M | - |
| Net margin | -5.6% | - |
| SEC filings | 885 | 947 |
Full pages: Esperion Therapeutics, Inc. and Novartis AG, or browse the full rankings.